The mRNA Corona vaccine BCV-193N from baseclick Vaccine GmbH was positively assessed in the Scientific Advice Meeting at the Paul Ehrlich Institute and is now being further developed clinically

Neuried, Germany, October 29th, 2021 - the German company baseclick Vaccine GmbH presented its preclinical data to the Paul Ehrlich Institute in a Scientific Advice Meeting, the outline for the production of its sugar-modified mRNA vaccine and phase I clinical study. The Paul Ehrlich Institute has come to a positive assessment of the novel mRNA vaccine candidate and sees no problems in further clinical development.

In contrast to the currently approved mRNA vaccines, the corona vaccine candidate BCV-193N is a non-encapsulated mRNA vaccine that encodes the SARS-CoV-2 nucleocapsid protein (N-protein) and is linked to a sugar. The sugar serves as a cell targeting agent and stabilizes and protects the mRNA vaccine. BCV-193N is mainly taken up by immune competent cells and the viral N-protein is presented to the immune system. The predominant immune response is a T-cell activation. When infected with SARS-CoV-2, the T cells attack and eliminate the infected cells and suppress further infection.

The composition of BCV-193N therefore differs in two aspects from the currently approved mRNA vaccines from BioNTech/Pfizer and Moderna, which present the viral spike protein (S-protein) to the immune system and are formulated in lipid nanoparticles (LNP).

After the positive evaluation of BCV-193N by the Paul Ehrlich Institute, the vaccine is now further developed in a combined safety-dose-finding study. **Dr. Thomas Frischmuth**, **CEO of baseclick GmbH** and developer of the new mRNA vaccine concept, welcomed the positive feedback: "We are pleased that the Paul Ehrlich Institute gave a positive evaluation of the preclinical data. baseclick Vaccine and our cooperation partners have done a great job and we will again mobilize all our resources to prepare the first-in-human FIH study."

About baseclick GmbH:

baseclick GmbH is a leading biotechnological company and was founded in 2008 from the Ludwig Maximilian University of Munich by Prof. Dr. Thomas Carell spin-off. With the so-called “Click Chemistry”, discovered by the Nobel laureate in chemistry, Prof. Dr. Barry Sharpless, baseclick GmbH has used various modifications of nucleic acids. The technology is used in many products such as EdU cell proliferation kits, modifications of oligonucleotides, marking of nucleotides for

the “Next Generation Sequencing” (NGS) method, mRNA preparation kit and for NGS diagnostic applications. Baseclick GmbH, based in Neuried, Germany, has out-licensed its patented technology to numerous leading companies worldwide. Based on its extensive expertise in the modification of DNA and RNA, baseclick is increasingly researching modern next-generation therapeutic approaches and developing nucleic acid-based drugs. Baseclick GmbH works side by side with world-renowned cooperation partners from the pharmaceutical industry and universities.

About baseclick Vaccine GmbH:

baseclick Vaccine GmbH is a German company and was founded in 2020 as a pharmaceutical subsidiary of baseclick GmbH. Despite the successful approvement of COVID-19 mRNA vaccines, the improvement of vaccines against a variety of infectious pathogens has to be followed. Therefore, baseclick Vaccine GmbH researches on modern therapeutic approaches based on mRNA in order to rapidly advance the development of novel vaccines. With the click technology, a bioconjugation method to connect biomolecules, we believe we have found the solution.

Further information can be found at: https://www.baseclick.eu/baseclick-vaccine/

Contact:
baseclick Vaccine GmbH
Floriansbogen 2-4
82061 Neuried
Germany
Phone: +49 89 9699 3404
Email: admin@baseclick.eu